Loading…
Reported covered position: CoS, Representative Bean
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
U.S. Innovation and Global Competitiveness Act of 2026
Client: MUNICH AMERICAN REASSURANCE COMPANY · Firm: TIBER CREEK GROUP
Issues related to appropriate tax treatment of reinsurance firms/transactions; Issues related to H.R. 10431 - U.S. Innovation and Global Competitiveness Act of 2026.
U.S. Innovation and Global Competitiveness Act of 2026
Client: CANADA LIFE REINSURANCE COMPANY · Firm: TIBER CREEK GROUP
Issues related to appropriate tax treatment of reinsurance firms/transactions; Issues related to H.R. 10431 - U.S. Innovation and Global Competitiveness Act of 2026.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ELEVANCE HEALTH, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to the Medicare Advantage and Medicaid programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) via TIBER CREEK GROUP
2026 · third_quarter · Q3
Source: Senate LDA
| U.S. CHAMBER OF COMMERCE - CENTER FOR CAPITAL MARKETS COMPETITIVENESS |
| 46 |
| 2009–2019 |
| MICROSOFT CORPORATION | 45 | 2015–2026 |
| ENVIRONMENTAL DEFENSE ACTION FUND | 44 | 2013–2026 |
| MERCK & CO., INC. | 40 | 2016–2026 |
| EMD SERONO, INC. | 39 | 2017–2026 |
| TIBER CREEK HEALTH STRATEGIES, INC. ON BEHALF OF GENENTECH, INC. | 39 | 2011–2026 |
| BUSINESS ROUNDTABLE | 38 | 2009–2019 |
| MMM HEALTHCARE | 36 | 2014–2024 |
| MASTERCARD | 35 | 2009–2023 |
| ENTERGY SERVICES, LLC | 34 | 2009–2018 |
| LEGACY COMMUNITY HEALTH SERVICES | 34 | 2014–2023 |
| THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY | 34 | 2019–2026 |
| JAZZ PHARMACEUTICALS | 33 | 2019–2026 |
| FAIR ISAAC CORPORATION (FICO) | 31 | 2011–2018 |
| TIBER CREEK HEALTH STRATEGIES, INC. ON BEHALF OF ELI LILLY AND COMPANY | 28 | 2020–2026 |
| BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) | 27 | 2020–2025 |
| SECRETARY OF STATE, STATE OF DELAWARE | 27 | 2009–2023 |
| THE BUSINESS ROUNDTABLE | 27 | 2019–2025 |
| AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION | 26 | 2009–2015 |
| CHUBB INA HOLDINGS INC | 26 | 2009–2015 |
| DEUTSCHE BANK USA (FKA DEUTSCHE BANK SECURITIES INC.) | 26 | 2009–2015 |
| LEON MEDICAL CENTER | 26 | 2009–2015 |
| PMI GLOBAL SERVICES INC. | 26 | 2009–2014 |
| SB ENERGY DEVCO (US), INC. | 26 | 2020–2026 |
| AMERICAN HOTEL & LODGING ASSOCIATION | 25 | 2016–2022 |
| HARLEY-DAVIDSON FINANCIAL SERVICES, INC. | 25 | 2009–2015 |
| ONE ACTION | 25 | 2018–2024 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 24 | 2009–2015 |
| CAPG | 24 | 2014–2019 |
| ICKES & ENRIGHT GROUP (NORTHWELL HEALTH FKA NORTH SHORE-LIJ) | 24 | 2010–2015 |
| NATIONAL ASSN OF BROADCASTERS | 24 | 2017–2022 |
| SB GROUP US, INC. DBA SOFTBANK GROUP US, INC. | 24 | 2021–2026 |
| CANADA LIFE REINSURANCE COMPANY | 23 | 2021–2026 |
| HANNOVER LIFE REASSURANCE COMPANY OF AMERICA | 23 | 2021–2026 |
| MUNICH AMERICAN REASSURANCE COMPANY | 23 | 2021–2026 |
| TAKEDA PHARMACEUTICALS AMERICA INC | 23 | 2021–2026 |
| PENTAGON FEDERAL CREDIT UNION | 22 | 2009–2014 |
| U.S. CHAMBER OF COMMERCE FKA U.S. CHAMBER OF COMMERCE-INSTITUTE FOR LEGAL REFORM | 22 | 2009–2026 |
| UNITED SERVICES AUTOMOBILE ASSOCIATION | 22 | 2009–2014 |
| NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS (FKA NAHU) | 21 | 2015–2019 |
| NYSE GROUP INC | 21 | 2009–2013 |
| FACEBOOK, INC. | 20 | 2012–2019 |
| AMERICAN INSTITUTE OF CERTIFIED PUBLIC ACCOUNTANTS | 19 | 2009–2013 |
| ACCENTURE | 18 | 2010–2018 |
| DAIRY FARMERS OF CANADA | 18 | 2021–2025 |
| GRID UNITED LLC | 18 | 2022–2026 |
| NEW YORK LIFE INSURANCE COMPANY | 18 | 2010–2014 |
| THE CAPITAL GROUP COMPANIES, INC. AND ITS AFFILIATES | 18 | 2015–2019 |
| BROWARD COUNTY FLORIDA | 17 | 2013–2016 |
| BUSINESS SOFTWARE ALLIANCE | 17 | 2015–2019 |
| INTERNATIONAL SWAPS AND DERIVATIVES ASSOCIATION | 17 | 2009–2013 |
| UNIVISION COMMUNICATIONS INC. | 17 | 2018–2021 |
| Alnylam Pharmaceuticals, Inc. | 16 | 2023–2026 |
| GILEAD SCIENCES, INC. | 16 | 2023–2026 |
| VIEW | 15 | 2021–2024 |
| CUBA DEMOCRACY PUBLIC ADVOCACY, CORP. | 14 | 2013–2016 |
| ELEVANCE HEALTH, INC. | 14 | 2009–2026 |
| PREVENT OPIOID ABUSE | 14 | 2020–2023 |
| UBER TECHNOLOGIES INC. | 14 | 2017–2021 |
| AT&T SERVICES, INC. | 13 | 2011–2013 |
| WHIRLPOOL CORPORATION | 13 | 2012–2015 |
| ANTI-DEFAMATION LEAGUE | 12 | 2014–2017 |
| CIT GROUP INC | 12 | 2011–2013 |
| PAY OUR INTERNS, INC. | 12 | 2018–2020 |
| PHLOW CORPORATION | 12 | 2021–2023 |
| ABBVIE, INC. | 11 | 2013–2015 |
| ALLIANCE FOR QUALITY NURSING HOME CARE | 11 | 2009–2012 |
| BOYD GAMING CORPORATION | 11 | 2010–2012 |
| MALARIA NO MORE | 11 | 2024–2026 |
| THE ALLSTATE CORPORATION | 11 | 2009–2011 |
| BIOSCRIP | 10 | 2017–2019 |
| CELGENE CORPORATION | 10 | 2018–2019 |
| HEALTHSPRING, INC. | 10 | 2011–2013 |
| ROIVANT SCIENCES, INC. | 10 | 2018–2020 |
| BRISTOL MYERS SQUIBB | 9 | 2020–2021 |
| COALITION FOR THE AMERICAN DREAM | 9 | 2019–2020 |
| UNUM GROUP | 9 | 2012–2014 |
| VERTEX PHARMACEUTICALS | 9 | 2011–2025 |
| AIRBUS AMERICAS, INC. | 8 | 2023–2024 |
| EVERGLADES PROTECTION ALLIANCE, INC. | 8 | 2021–2022 |
| FORD MOTOR COMPANY | 8 | 2010–2012 |
| JULIAN ROBERTSON | 8 | 2009–2010 |
| THE ICKES & ENRIGHT GROUP, INC. (O/B/O AMALGAMATED TRANSIT UNION, AFL-CIO) | 8 | 2012–2014 |
| TIBER CREEK HEALTH STRATEGIES, INC. (OBO COMPREHENSIVE HEALTH MANAGEMENT, INC.) | 8 | 2018–2019 |
| DELTA AIR LINES, INC. | 7 | 2018–2024 |
| MANAGED FUNDS ASSOCIATION | 7 | 2021–2022 |
| NATIONAL MUSIC PUBLISHERS ASSOCIATION | 7 | 2011–2013 |
| BAY BRIDGE STRATEGIES (ON BEHALF OF KINSA, INC.) | 6 | 2020–2021 |
| COMMITTEE ON CAPITAL MARKETS REGULATION | 6 | 2009–2010 |
| INTERNATIONAL FRANCHISE ASSOCIATION | 6 | 2020–2021 |
| MID-SIZE BANK COALITION OF AMERICA (MBCA) | 6 | 2013–2014 |
| QUALCOMM INC | 6 | 2021–2022 |
| STATE OF RHODE ISLAND | 6 | 2020–2021 |
| CORMEDIX, INC. | 5 | 2023–2024 |
U.S. Innovation and Global Competitiveness Act of 2026
Client: HANNOVER LIFE REASSURANCE COMPANY OF AMERICA · Firm: TIBER CREEK GROUP
Issues related to appropriate tax treatment of reinsurance firms/transactions; Issues related to H.R. 10431 - US Innovation and Global Competitiveness Act of 2026
Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Biosimilars Access and Affordability Act
Client: MERCK & CO., INC · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Litigation Transparency Act of 2025
Client: U.S. CHAMBER OF COMMERCE FKA U.S. CHAMBER OF COMMERCE-INSTITUTE FOR LEGAL REFORM · Firm: TIBER CREEK GROUP
Issues related to general litigation reform; Issues related to third party litigation funding; Issues related to H.R. 1109 - Litigation Transparency Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 2675/S. 3180 - Protecting Our Courts from Foreign Manipulation Act of 2025.
Litigation Transparency Act of 2025
Client: U.S. CHAMBER OF COMMERCE FKA U.S. CHAMBER OF COMMERCE-INSTITUTE FOR LEGAL REFORM · Firm: TIBER CREEK GROUP
Issues related to general litigation reform; Issues related to third party litigation funding; Issues related to H.R. 1109 - Litigation Transparency Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 2675/S. 3180 - Protecting Our Courts from Foreign Manipulation Act of 2025.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Maintaining Investments in New Innovation Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Protecting Our Courts from Foreign Manipulation Act
Client: U.S. CHAMBER OF COMMERCE FKA U.S. CHAMBER OF COMMERCE-INSTITUTE FOR LEGAL REFORM · Firm: TIBER CREEK GROUP
Issues related to general litigation reform; Issues related to third party litigation funding; Issues related to H.R. 1109 - Litigation Transparency Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 2675/S. 3180 - Protecting Our Courts from Foreign Manipulation Act of 2025.
Protecting Our Courts from Foreign Manipulation Act
Client: U.S. CHAMBER OF COMMERCE FKA U.S. CHAMBER OF COMMERCE-INSTITUTE FOR LEGAL REFORM · Firm: TIBER CREEK GROUP
Issues related to general litigation reform; Issues related to third party litigation funding; Issues related to H.R. 1109 - Litigation Transparency Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 2675/S. 3180 - Protecting Our Courts from Foreign Manipulation Act of 2025.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: MERCK & CO., INC · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: MERCK & CO., INC · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: MERCK & CO., INC · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
General immigration issues; Issues related to the Secure America Act (P.L. 119-98); Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to Temporary Protected Status (TPS), including ongoing federal and legal developments.
General immigration issues; Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to Temporary Protected Status (TPS), including ongoing federal and legal developments.
General immigration issues; Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to H.R. 8013 - Keep Innovators in America Act; Issues related to H.R. 7147 - Further Additional Continuing Appropriations Act, 2026; Issues related to Temporary Protected Status (TPS).
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.
Issues related to H.R. 6048/S. 3663 - NDO Fairness Act of 2026; Issues related to H.R. 7786/S. 3982 - AI Fraud Accountability Act of 2026; Issues related to S. 1748 - Kids Online Safety Act.
Issues related to H.R. 6048/S. 3663 - NDO Fairness Act of 2026; Issues related to H.R. 7786/S. 3982 - AI Fraud Accountability Act of 2026; Issues related to S. 1748 - Kids Online Safety Act.
SAFE Drugs Act of 2025
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Firm: TIBER CREEK GROUP
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509/S. 3794 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.
SAFE Drugs Act of 2025
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Firm: TIBER CREEK GROUP
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025; Issues related to FDA guidance on Alcohol Use Disorder (AUD).
SAFE Drugs Act of 2025
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Firm: TIBER CREEK GROUP
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.
Homeland Security and Further Additional Continuing Appropriations Act, 2026.
Client: FWD.US · Firm: TIBER CREEK GROUP
General immigration issues; Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to H.R. 8013 - Keep Innovators in America Act; Issues related to H.R. 7147 - Further Additional Continuing Appropriations Act, 2026; Issues related to Temporary Protected Status (TPS).
Issues related to H.R. 6048/S. 3663 - NDO Fairness Act of 2026; Issues related to H.R. 7786/S. 3982 - AI Fraud Accountability Act of 2026; Issues related to S. 1748 - Kids Online Safety Act.
Issues related to H.R. 6048/S. 3663 - NDO Fairness Act of 2026; Issues related to H.R. 7786/S. 3982 - AI Fraud Accountability Act of 2026; Issues related to S. 1748 - Kids Online Safety Act.
General immigration issues; Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to H.R. 8013 - Keep Innovators in America Act; Issues related to H.R. 7147 - Further Additional Continuing Appropriations Act, 2026; Issues related to Temporary Protected Status (TPS).
Guidelines for Use, Access, and Responsible Disclosure of Financial Data Act
Client: THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY · Firm: TIBER CREEK GROUP
Issues related to data privacy; Issues related to H.R. 8398 - Guidelines for Use, Access, and Responsible Disclosure of Financial Data Act; Issues related to H.R. 8413 - SECURE Data Act; Issues related to artificial intelligence; Issues related to Basel III Endgame capital requirements.
Guidelines for Use, Access, and Responsible Disclosure of Financial Data Act
Client: THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY · Firm: TIBER CREEK GROUP
Issues related to data privacy; Issues related to H.R. 8398 - Guidelines for Use, Access, and Responsible Disclosure of Financial Data Act; Issues related to H.R. 8413 - SECURE Data Act; Issues related to artificial intelligence; Issues related to Basel III Endgame capital requirements.
SECURE Data Act
Client: THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY · Firm: TIBER CREEK GROUP
Issues related to data privacy; Issues related to H.R. 8398 - Guidelines for Use, Access, and Responsible Disclosure of Financial Data Act; Issues related to H.R. 8413 - SECURE Data Act; Issues related to artificial intelligence; Issues related to Basel III Endgame capital requirements.
SECURE Data Act
Client: THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY · Firm: TIBER CREEK GROUP
Issues related to data privacy; Issues related to H.R. 8398 - Guidelines for Use, Access, and Responsible Disclosure of Financial Data Act; Issues related to H.R. 8413 - SECURE Data Act; Issues related to artificial intelligence; Issues related to Basel III Endgame capital requirements.
Making appropriations for national security, Department of State, and related programs for the fiscal year ending September 30, 2027, and for other purposes.
Client: DEMOCRATIC MAJORITY FOR ISRAEL · Firm: TIBER CREEK GROUP
Issues related to U.S.-Israel relations; Issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027; Issues related to H.R. 8595 - National Security, Department of State, and Related Programs Appropriations Act, 2027.
Making appropriations for national security, Department of State, and related programs for the fiscal year ending September 30, 2027, and for other purposes.
Client: MALARIA NO MORE · Firm: TIBER CREEK GROUP
Issues related to U.S. Bilateral and Multilateral Global Health program funding and appropriations, including Malaria; Issues related to H.R. 8595 - National Security, Department of State, and Related Programs Appropriations Act, 2027.
Making appropriations for national security, Department of State, and related programs for the fiscal year ending September 30, 2027, and for other purposes.
Client: MALARIA NO MORE · Firm: TIBER CREEK GROUP
Issues related to U.S. Bilateral and Multilateral Global Health program funding and appropriations, including Malaria; Issues related to H.R. 8595 - National Security, Department of State, and Related Programs Appropriations Act, 2027.
Making appropriations for national security, Department of State, and related programs for the fiscal year ending September 30, 2027, and for other purposes.
Client: DEMOCRATIC MAJORITY FOR ISRAEL · Firm: TIBER CREEK GROUP
Issues related to U.S.-Israel relations; Issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027; Issues related to H.R. 8595 - National Security, Department of State, and Related Programs Appropriations Act, 2027; Issues related to S.Res.852 - A resolution requesting information on Israel's human rights practices pursuant to section 502B(c) of the Foreign Assistance Act of 1961.
National Defense Authorization Act for Fiscal Year 2027
Client: U.S. CHAMBER OF COMMERCE FKA U.S. CHAMBER OF COMMERCE-INSTITUTE FOR LEGAL REFORM · Firm: TIBER CREEK GROUP
Issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027; Issues related to S. 4894 - FUSE Act; Issues related to foreign third-party litigation funding.
National Defense Authorization Act for Fiscal Year 2027
Client: DEMOCRATIC MAJORITY FOR ISRAEL · Firm: TIBER CREEK GROUP
Issues related to U.S.-Israel relations; Issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027; Issues related to H.R. 8595 - National Security, Department of State, and Related Programs Appropriations Act, 2027.
National Defense Authorization Act for Fiscal Year 2027
Client: DEMOCRATIC MAJORITY FOR ISRAEL · Firm: TIBER CREEK GROUP
Issues related to U.S.-Israel relations; Issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027; Issues related to H.R. 8595 - National Security, Department of State, and Related Programs Appropriations Act, 2027; Issues related to S.Res.852 - A resolution requesting information on Israel's human rights practices pursuant to section 502B(c) of the Foreign Assistance Act of 1961.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Issues related to H.R. 9102 - Biotech Investment National Security Act of 2026 (BINSA).
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Issues related to H.R. 6048/S. 3663 - NDO Fairness Act of 2026; Issues related to H.R. 7786/S. 3982 - AI Fraud Accountability Act of 2026; Issues related to S. 1748 - Kids Online Safety Act.
Issues related to H.R. 6048/S. 3663 - NDO Fairness Act of 2026; Issues related to H.R. 7786/S. 3982 - AI Fraud Accountability Act of 2026; Issues related to S. 1748 - Kids Online Safety Act.
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.
Issues related to intellectual property protections; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.
Issues related to intellectual property protections; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.
Protecting Our Courts from Foreign Manipulation Act of 2025
Client: U.S. CHAMBER OF COMMERCE FKA U.S. CHAMBER OF COMMERCE-INSTITUTE FOR LEGAL REFORM · Firm: TIBER CREEK GROUP
Issues related to general litigation reform; Issues related to third party litigation funding; Issues related to H.R. 1109 - Litigation Transparency Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 2675/S. 3180 - Protecting Our Courts from Foreign Manipulation Act of 2025.
Protecting Our Courts from Foreign Manipulation Act of 2025
Client: U.S. CHAMBER OF COMMERCE FKA U.S. CHAMBER OF COMMERCE-INSTITUTE FOR LEGAL REFORM · Firm: TIBER CREEK GROUP
Issues related to general litigation reform; Issues related to third party litigation funding; Issues related to H.R. 1109 - Litigation Transparency Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 2675/S. 3180 - Protecting Our Courts from Foreign Manipulation Act of 2025.
ASAP Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Firm: TIBER CREEK GROUP
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to S. 3267 - ASAP Act.
General immigration issues; Issues related to the Secure America Act (P.L. 119-98); Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to Temporary Protected Status (TPS), including ongoing federal and legal developments.
General immigration issues; Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to Temporary Protected Status (TPS), including ongoing federal and legal developments.
General immigration issues; Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to H.R. 8013 - Keep Innovators in America Act; Issues related to H.R. 7147 - Further Additional Continuing Appropriations Act, 2026; Issues related to Temporary Protected Status (TPS).
Issues related to H.R. 6048/S. 3663 - NDO Fairness Act of 2026; Issues related to H.R. 7786/S. 3982 - AI Fraud Accountability Act of 2026; Issues related to S. 1748 - Kids Online Safety Act.
Issues related to H.R. 6048/S. 3663 - NDO Fairness Act of 2026; Issues related to H.R. 7786/S. 3982 - AI Fraud Accountability Act of 2026; Issues related to S. 1748 - Kids Online Safety Act.
SAFE Drugs Act of 2026
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Firm: TIBER CREEK GROUP
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509/S. 3794 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.
Issues related to H.R. 6048/S. 3663 - NDO Fairness Act of 2026; Issues related to H.R. 7786/S. 3982 - AI Fraud Accountability Act of 2026; Issues related to S. 1748 - Kids Online Safety Act.
Issues related to H.R. 6048/S. 3663 - NDO Fairness Act of 2026; Issues related to H.R. 7786/S. 3982 - AI Fraud Accountability Act of 2026; Issues related to S. 1748 - Kids Online Safety Act.
FUSE Act
Client: U.S. CHAMBER OF COMMERCE FKA U.S. CHAMBER OF COMMERCE-INSTITUTE FOR LEGAL REFORM · Firm: TIBER CREEK GROUP
Issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027; Issues related to S. 4894 - FUSE Act; Issues related to foreign third-party litigation funding.
Chinese Military and Surveillance Company Sanctions Act of 2024
Client: AMGEN INC · Firm: TIBER CREEK GROUP
Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Chinese Military and Surveillance Company Sanctions Act of 2024
Client: MERCK & CO., INC · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act.
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R.1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D and Part B Pricing Reform; Issues related to home infusion under Medicare FFS; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation (MINI) Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to H.R. 946/S.1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R.1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Issues related to international trade; Issues related to intellectual property protections for COVID-19 treatments; Issues related to the TRIPS Waiver; Global supply chain issues, including H.R. 2213/S. 998 - Medical Supply Chain Resiliency Act; Issues related to compulsory licensing and other intellectual property issues in multiple countries.
Issues related to international trade; Issues related to intellectual property protections for COVID-19 treatments; Issues related to the TRIPS Waiver; Global supply chain issues, including H.R. 2213/S. 998 - Medical Supply Chain Resiliency Act; Issues related to compulsory licensing and other intellectual property issues in multiple countries.
Issues related to international trade; Issues related to intellectual property protections for COVID-19 treatments; Issues related to the TRIPS Waiver; Global supply chain issues, including H.R. 2213/S. 998 - Medical Supply Chain Resiliency Act; Issues related to compulsory licensing and other intellectual property issues in multiple countries.
Treat and Reduce Obesity Act of 2025
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Firm: TIBER CREEK GROUP
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.
Treat and Reduce Obesity Act of 2025
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Firm: TIBER CREEK GROUP
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: MERCK & CO., INC · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: MERCK & CO., INC · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to S. 3267 - ASAP Act.
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509/S. 3794 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); General intellectual property issues; Issues related to pharmacy benefit managers; Issues related to Most Favored Nation (MFN) policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to tariff policy and supply chain policy.
Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to 340B Drug Pricing Program; General intellectual property issues; Issues related to pharmacy benefit managers; Issues related to Most Favored Nation (MFN) policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRID UNITED LLC via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to electricity transmission and permitting reform.
Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
General immigration issues; Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to Temporary Protected Status (TPS), including ongoing federal and legal developments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEMOCRATIC MAJORITY FOR ISRAEL via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to U.S.-Israel relations; Issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027; Issues related to H.R. 8595 - National Security, Department of State, and Related Programs Appropriations Act, 2027; Issues related to S.Res.852 - A resolution requesting information on Israel's human rights practices pursuant to section 502B(c) of the Foreign Assistance Act of 1961.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROSOFT CORPORATION via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to H.R. 6048/S. 3663 - NDO Fairness Act of 2026; Issues related to H.R. 7786/S. 3982 - AI Fraud Accountability Act of 2026; Issues related to S. 1748 - Kids Online Safety Act.
Issues related to competition in the technology sector.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to oncology; Issues related to ophthalmology; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF GENENTECH, INC.) via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to Medicare Part B Pricing Reform; Issues relating to Medicaid Pricing Reform.
Issues related to the 340B Program - Public Health Service Act (PL 78-410).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Pricing Reform.
Issues related to intellectual property protections; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO., INC via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to intellectual property protections.
Issues related to immunization policy.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to reproductive healthcare and IVF.
Issues related to Medicare Part D and Part B Pricing Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENVIRONMENTAL DEFENSE ACTION FUND via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to climate change and carbon pricing; Issues related to environmental regulations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to data privacy; Issues related to H.R. 8398 - Guidelines for Use, Access, and Responsible Disclosure of Financial Data Act; Issues related to H.R. 8413 - SECURE Data Act; Issues related to artificial intelligence; Issues related to Basel III Endgame capital requirements.
Issues related to insurance regulation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MALARIA NO MORE via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to U.S. Bilateral and Multilateral Global Health programs, including Malaria.
Issues related to U.S. Bilateral and Multilateral Global Health program funding and appropriations, including Malaria; Issues related to H.R. 8595 - National Security, Department of State, and Related Programs Appropriations Act, 2027.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SB GROUP US DBA SOFTBANK GROUP US, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SB ENERGY DEVCO (US), INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to implementation of the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
MUNICH AMERICAN REASSURANCE COMPANY via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to appropriate tax treatment of reinsurance firms/transactions; Issues related to H.R. 10431 - U.S. Innovation and Global Competitiveness Act of 2026.
Issues related to appropriate tax treatment of reinsurance firms/transactions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HANNOVER LIFE REASSURANCE COMPANY OF AMERICA via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to appropriate tax treatment of reinsurance firms/transactions.
Issues related to appropriate tax treatment of reinsurance firms/transactions; Issues related to H.R. 10431 - US Innovation and Global Competitiveness Act of 2026
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CANADA LIFE REINSURANCE COMPANY via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to appropriate tax treatment of reinsurance firms/transactions; Issues related to H.R. 10431 - U.S. Innovation and Global Competitiveness Act of 2026.
Issues related to appropriate tax treatment of reinsurance firms/transactions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JAZZ PHARMACEUTICALS via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to the FDA and Health and Human Services pertaining to CBD policies; Issues related to the regulation of intoxicating hemp.
Issues related to cannabis research; Issues related to the FDA; Issues related to cannabis research at Health and Human Services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
U.S. CHAMBER OF COMMERCE FKA U.S. CHAMBER OF COMMERCE-INSTITUTE FOR LEGAL REFORM via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to general litigation reform; Issues related to third party litigation funding; Issues related to H.R. 1109 - Litigation Transparency Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 2675/S. 3180 - Protecting Our Courts from Foreign Manipulation Act of 2025.
Issues related to general litigation reform; Issues related to third party litigation funding; Issues related to H.R. 1109 - Litigation Transparency Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 2675/S. 3180 - Protecting Our Courts from Foreign Manipulation Act of 2025.
MICROSOFT CORPORATION via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to competition in the technology sector.
Issues related to H.R. 6048/S. 3663 - NDO Fairness Act of 2026; Issues related to H.R. 7786/S. 3982 - AI Fraud Accountability Act of 2026; Issues related to S. 1748 - Kids Online Safety Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
ELEVANCE HEALTH, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to the Medicare Advantage and Medicaid programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF GENENTECH, INC.) via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to Medicare Part B Pricing Reform; Issues relating to Medicaid Pricing Reform.
Issues related to the 340B Program - Public Health Service Act (PL 78-410).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to intellectual property protections; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Pricing Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO., INC via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026.
Issues related to immunization policy.
Issues related to intellectual property protections.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to reproductive healthcare and IVF.
Issues related to Medicare Part D and Part B Pricing Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JAZZ PHARMACEUTICALS via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to the FDA and Health and Human Services pertaining to CBD policies; Issues related to the regulation of intoxicating hemp.
Issues related to cannabis research; Issues related to the FDA; Issues related to cannabis research at Health and Human Services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTRAZENECA via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to H.R. 9102 - Biotech Investment National Security Act of 2026 (BINSA).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MALARIA NO MORE via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to U.S. Bilateral and Multilateral Global Health programs, including Malaria.
Issues related to U.S. Bilateral and Multilateral Global Health program funding and appropriations, including Malaria; Issues related to H.R. 8595 - National Security, Department of State, and Related Programs Appropriations Act, 2027.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.
Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SB GROUP US DBA SOFTBANK GROUP US, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SB ENERGY DEVCO (US), INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to implementation of the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
MUNICH AMERICAN REASSURANCE COMPANY via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to appropriate tax treatment of reinsurance firms/transactions.
Issues related to appropriate tax treatment of reinsurance firms/transactions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HANNOVER LIFE REASSURANCE COMPANY OF AMERICA via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to appropriate tax treatment of reinsurance firms/transactions.
Issues related to appropriate tax treatment of reinsurance firms/transactions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CANADA LIFE REINSURANCE COMPANY via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to appropriate tax treatment of reinsurance firms/transactions.
Issues related to appropriate tax treatment of reinsurance firms/transactions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to insurance regulation.
Issues related to data privacy; Issues related to H.R. 8398 - Guidelines for Use, Access, and Responsible Disclosure of Financial Data Act; Issues related to H.R. 8413 - SECURE Data Act; Issues related to artificial intelligence; Issues related to Basel III Endgame capital requirements.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENVIRONMENTAL DEFENSE ACTION FUND via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to climate change and carbon pricing; Issues related to environmental regulations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
GILEAD SCIENCES, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to oncology; Issues related to ophthalmology; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); General intellectual property issues; Issues related to pharmacy benefit managers; Issues related to Most Favored Nation (MFN) policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to tariff policy and supply chain policy.
GRID UNITED LLC via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to electricity transmission and permitting reform.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
General immigration issues; Issues related to the Secure America Act (P.L. 119-98); Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to Temporary Protected Status (TPS), including ongoing federal and legal developments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEMOCRATIC MAJORITY FOR ISRAEL via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to U.S.-Israel relations; Issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027; Issues related to H.R. 8595 - National Security, Department of State, and Related Programs Appropriations Act, 2027.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to oncology; Issues related to ophthalmology; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); General intellectual property issues; Issues related to pharmacy benefit managers; Issues related to Most Favored Nation (MFN) policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to 340B Drug Pricing Program; General intellectual property issues; Issues related to pharmacy benefit managers; Issues related to Most Favored Nation (MFN) policy.
Issues related to tariff policy and supply chain policy.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
GRID UNITED LLC via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to electricity transmission and permitting reform.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
General immigration issues; Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to H.R. 8013 - Keep Innovators in America Act; Issues related to H.R. 7147 - Further Additional Continuing Appropriations Act, 2026; Issues related to Temporary Protected Status (TPS).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEMOCRATIC MAJORITY FOR ISRAEL via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to U.S.-Israel relations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELEVANCE HEALTH, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to the Medicare Advantage and Medicaid programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to data privacy; Issues related to artificial intelligence; Issues related to Basel III Endgame capital requirements.
Issues related to insurance regulation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SB GROUP US DBA SOFTBANK GROUP US, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SB ENERGY DEVCO (US), INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to implementation of the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
MUNICH AMERICAN REASSURANCE COMPANY via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to appropriate tax treatment of reinsurance transactions in the One Big Beautiful Bill Act (PL 119-21).
Issues related to appropriate tax treatment of reinsurance firms/transactions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HANNOVER LIFE REASSURANCE COMPANY OF AMERICA via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to appropriate tax treatment of reinsurance firms/transactions.
Issues related to appropriate tax treatment of reinsurance firms/transactions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CANADA LIFE REINSURANCE COMPANY via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to appropriate tax treatment of reinsurance firms/transactions.
Issues related to appropriate tax treatment of reinsurance firms/transactions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENVIRONMENTAL DEFENSE ACTION FUND via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to climate change and carbon pricing; Issues related to environmental regulations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
JAZZ PHARMACEUTICALS via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to the FDA and Health and Human Services pertaining to CBD policies; Issues related to the regulation of intoxicating hemp.
Issues related to cannabis research; Issues related to the FDA; Issues related to cannabis research at Health and Human Services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROSOFT CORPORATION via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to competition in the technology sector.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025; Issues related to FDA guidance on Alcohol Use Disorder (AUD).
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
MALARIA NO MORE via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to U.S. Bilateral and Multilateral Global Health programs, including Malaria.
Issues related to U.S. Bilateral and Multilateral Global Health program funding and appropriations, including Malaria; Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF GENENTECH, INC.) via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to clinical trial diversity.
Issues related to Medicare Part B Pricing Reform; Issues relating to Medicaid Pricing Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Issues related to Plasma-Derived Therapies; Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to National Priority Voucher (CNPV) program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Pricing Reform.
Issues related to intellectual property protections; Issues related to tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO., INC via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to vaccine policy.
Issues related to intellectual property protections.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to reproductive healthcare and IVF.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via TIBER CREEK GROUP
2026 · first_quarter · RA
Issues related to pharmaceutical innovation and pricing.
DEMOCRATIC MAJORITY FOR ISRAEL via TIBER CREEK GROUP
2026 · first_quarter · RR
Issues related to the U.S.-Israel relationship and Middle East policy.
EMD SERONO, INC. via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Issues related to reproductive healthcare and IVF.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO., INC via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Issues related to intellectual property protections.
Issues related to vaccine policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Q4
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Pricing Reform.
Issues related to intellectual property protections; Issues related to Tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Issues related to Plasma-Derived Therapies; Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to National Priority Voucher (CNPV) program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF GENENTECH, INC.) via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to Medicare Part B Pricing Reform; Issues relating to Medicaid Pricing Reform.
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to clinical trial diversity.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to tariff policy and supply chain policy.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
GRID UNITED LLC via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issue related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to electricity transmission and permitting reform.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Q4
General immigration issues; Issues related to the Deferred Action for Childhood Arrivals policy; Issues related to immigration in the homeland and judiciary titles.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to insurance regulation.
Issues related to data privacy; Issues related to artificial intelligence; Issues related to Basel III Endgame capital requirements.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELEVANCE HEALTH, INC. via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to the Medicare Advantage and Medicaid programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICROSOFT CORPORATION via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to competition in the technology sector.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MALARIA NO MORE via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to U.S. Bilateral and Multilateral Global Health programs, including Malaria.
Issues related to U.S. Bilateral and Multilateral Global Health program funding and appropriations, including Malaria; H.R. 4779 - National Security, Department of State, and Related Programs Appropriations Act, 2026.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SB ENERGY DEVCO (US), INC. via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to implementation of the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SB GROUP US DBA SOFTBANK GROUP US, INC. via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MUNICH AMERICAN REASSURANCE COMPANY via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Advocating for appropriate tax treatment of reinsurance firms/transactions.
Advocating for appropriate tax treatment of reinsurance transactions in the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HANNOVER LIFE REASSURANCE COMPANY OF AMERICA via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Advocating for appropriate tax treatment of reinsurance firms/transactions.
Advocating for appropriate tax treatment of reinsurance firms/transactions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027; Issues related to S. 4894 - FUSE Act; Issues related to foreign third-party litigation funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to 340B Drug Pricing Program; General intellectual property issues; Issues related to pharmacy benefit managers; Issues related to Most Favored Nation (MFN) policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to 340B Drug Pricing Program; General intellectual property issues; Issues related to pharmacy benefit managers; Issues related to Most Favored Nation (MFN) policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE